期刊
SAUDI JOURNAL OF BIOLOGICAL SCIENCES
卷 26, 期 6, 页码 1146-1153出版社
ELSEVIER
DOI: 10.1016/j.sjbs.2019.05.001
关键词
HeLa cells; ALL; L-asparaginase; Pseudomonas aeruginosa
类别
Among cancers, acute lymphoblastic leukemia (ALL) occurs in the children <15 years of age. L-asparaginase is an important therapeutic enzyme used for treating ALL. Owing to its therapeutic use and demand, microorganisms have been in use for many years to produce L-asparaginase on an industrial scale. Gram-negative bacteria (Serratia, Erwinia and Escherichia coli) species were used in L-asparaginase. However, earlier studies have documented that the long-term use of enzymes produced from these commercial strains induces hypersensitivity in patients. Therefore, there is a need to discover novel microbial strains producing L-asparaginase with anti-cancer properties, which can be employed for the commercial production of the enzyme. In this study, three strains of Pseudomonas aeruginosa (accession numbers LC425424 (P31), LC425425 (P32), and LC425426 (P34)) isolated from garden soil were screened for the invention of L-asparaginase. Fermented production media was dialyzed to attain the purified enzyme, thus showed a dose-depended cytotoxic effect on HeLa cells, as determined by MTT assay. The IC(50)s of the different isolates were 86.73, 57.65, and 40.34 mu g/mL. These results indicate that pseudomonal L-asparaginase may be used for cancer treatment. (C) 2019 Production and hosting by Elsevier B.V. on behalf of King Saud University.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据